All In Biotech

Drug Trial Radar · NCT03683719

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

A Phase 2b, Double-blind, Randomised, 5-arm, Vehicle-controlled, Dose-ranging Trial to Evaluate the Efficacy and Safety of Twice Daily Topical Application of Delgocitinib Cream 1, 3, 8, and 20 mg/g for 16 Weeks in Adult Subjects With Mild to Severe Chronic Hand Eczema

Last checked: Nov 20, 2026Latest source record: Mar 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 258 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

258

Actual

Start

Nov 28, 2018

Primary completion

Mar 6, 2020

Study completion Apr 20, 2020

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Sep 25, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research trial was to test different strengths of a new trial medication, delgocitinib cream 1, 3, 8, and 20 mg/g, and to investigate how treatment with delgocitinib cream affects chronic hand eczema. This was judged by a range of assessments that rate the severity and extent of chronic hand eczema and its symptoms, as well as general health status and quality of life.

Conditions

  • Chronic Hand Eczema

Interventions

  • Delgocitinib creamDrug

    Cream for topical application.

  • Delgocitinib cream vehicleDrug

    The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator's Global Assessment for Chronic Hand Eczema (IGA-CHE) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-step Improvement (IGA-CHE Treatment Success) From Baseline to Week 16.Time frame: Week 0 to Week 16.

Locations

28 sites in 3 countries. Site status is shown where the registry gives one.

  • Leo Pharma Investigational Site

    Tucson, Arizona

  • Leo Pharma Investigational Site

    Hialeah, Florida

  • Leo Pharma Investigational Site

    Portland, Oregon

  • Leo Pharma Investigational Site

    Portland, Oregon

  • Leo Pharma Investigational Site

    Aarhus, Denmark

  • Leo Pharma Investigational Site

    Copenhagen, Denmark

  • Leo Pharma Investigational Site

    Hellerup, Denmark

  • LEO Pharma Investigational Site

    Herlev, Denmark

  • Leo Pharma Investigational Site

    Berlin, Germany

  • Leo Pharma Investigational Site

    Bochum, Germany

  • Leo Pharma Investigational Site

    Bremerhaven, Germany

  • Leo Pharma Investigational Site

    Dresden, Germany

  • Leo Pharma Investigational Site

    Düsseldorf, Germany

  • Leo Pharma Investigational Site

    Gera, Germany

  • Leo Pharma Investigational Site

    Göttingen, Germany

  • Leo Pharma Investigational Site

    Jena, Germany

  • Leo Pharma Investigational Site

    Kiel, Germany

  • Leo Pharma Investigational Site

    Kiel, Germany

  • Leo Pharma Investigational Site

    Langenau, Germany

  • Leo Pharma Investigational Site

    Lübeck, Germany

  • Leo Pharma Investigational Site

    Mahlow, Germany

  • Leo Pharma Investigational Site

    Mainz, Germany

  • Leo Pharma Investigational Site

    Memmingen, Germany

  • Leo Pharma Investigational Site

    München, Germany

  • Leo Pharma Investigational Site

    Selters, Germany

  • Leo Pharma Investigational Site

    Stuttgart, Germany

  • Leo Pharma Investigational Site

    Stuttgart, Germany

  • Leo Pharma Investigational Site

    Wuppertal, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.